<\/p>\n
Udimax 300<\/strong> \u00e4r ursodeoxycholic acid (UDCA) 300 mg<\/strong> — a hydrophilic bile acid that is the standard of care for primary biliary cholangitis (PBC), cholesterol gallstones in patients unfit for surgery, intrahepatic cholestasis of pregnancy (ICP), bile-acid diarrhoea, and pruritus of cholestatic liver disease<\/strong>. UDCA reduces cholesterol saturation in bile, replaces toxic hydrophobic bile acids in the bile-acid pool, exerts cytoprotective and anti-apoptotic effects on hepatocytes and cholangiocytes, and stimulates bicarbonate-rich choleresis. Standard adult doses range from 10–15 mg\/kg\/day for PBC and gallstones to 14–30 mg\/kg\/day for cholestasis of pregnancy<\/strong>. WHO-GMP certified manufacturer.<\/p>\n<\/div>\n \ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n Udimax 300 is supplied from a WHO-GMP-certifierad tillverkare<\/strong>. Varje best\u00e4llning skickas diskret \u00f6ver hela v\u00e4rlden och omfattas av v\u00e5r Reshipment Assurance Policy<\/a> — if it does not arrive within 20 business days, we reship at no cost. UDCA has been on the WHO Essential Medicines List for decades and is the cornerstone of medical therapy for cholestatic liver disease.<\/p>\n UDCA is a naturally occurring hydrophilic 7β-hydroxy bile acid (“the bear bile acid”). When taken orally it enriches the bile-acid pool, replacing toxic hydrophobic acids (chenodeoxycholic, lithocholic) that damage cholangiocytes and hepatocytes in cholestasis. Three actions matter clinically: (1) it reduces biliary cholesterol saturation, dissolving cholesterol gallstones over months; (2) it exerts direct cytoprotective and anti-apoptotic effects on liver cells, reducing immune-mediated damage in PBC; (3) it stimulates a bicarbonate-rich “alkaline tide” choleresis, which protects cholangiocytes from the detergent action of hydrophobic bile acids. Onset of biochemical improvement in PBC is typically 2–6 months.<\/p>\nVarf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n
Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n
Mekanism<\/h2>\n
Indications & doses<\/h2>\n